Impact of Treatment of Non-bleeding Complications of Cirrhosis on the Risk of Variceal Bleeding
暂无分享,去创建一个
R. Moreau | J. Abraldes | T. Reiberger | G. Garcia‐Tsao | A. Albillos | C. Ripoll | S. Augustin | F. Salerno
[1] R. Jalan,et al. Immunomodulatory and antioxidant function of albumin stabilises the endothelium and improves survival in a rodent model of chronic liver failure. , 2015, Journal of hepatology.
[2] Nahia Ezkurdia,et al. The renal effects of droxidopa are maintained in propranolol treated cirrhotic rats , 2015, Liver international : official journal of the International Association for the Study of the Liver.
[3] M. Naldi,et al. Posttranscriptional changes of serum albumin: Clinical and prognostic significance in hospitalized patients with cirrhosis , 2014, Hepatology.
[4] K. Massey,et al. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2 , 2014, Nature Medicine.
[5] J. Sánchez-Delgado,et al. Effects of intravenous albumin in patients with cirrhosis and episodic hepatic encephalopathy: a randomized double-blind study. , 2013, Journal of hepatology.
[6] R. Jalan,et al. Albumin: Pathophysiologic basis of its role in the treatment of cirrhosis and its complications , 2013, Hepatology.
[7] D. Thabut,et al. Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial. , 2013, JAMA.
[8] B. Runyon,et al. Introduction to the revised American Association for the Study of Liver Diseases Practice Guideline management of adult patients with ascites due to cirrhosis 2012 , 2013, Hepatology.
[9] A. Bhalla,et al. Midodrine and Clonidine in Patients With Cirrhosis and Refractory or Recurrent Ascites: A Randomized Pilot Study , 2013, The American Journal of Gastroenterology.
[10] Antonio Gasbarrini,et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute‐on‐chronic liver failure: The RELIEF trial , 2013, Hepatology.
[11] S. Ladas,et al. Long‐term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis , 2013, Journal of gastroenterology and hepatology.
[12] R. Navickis,et al. Albumin infusion improves outcomes of patients with spontaneous bacterial peritonitis: a meta-analysis of randomized trials. , 2013, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[13] D. Valla,et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. , 2012, Gastroenterology.
[14] Nahia Ezkurdia,et al. Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats , 2012, Hepatology.
[15] B. Procopet,et al. Letter: sorafenib in portal hypertension , 2012, Alimentary pharmacology & therapeutics.
[16] A. Krag,et al. Meta‐analysis: the safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia , 2012, Alimentary pharmacology & therapeutics.
[17] M. Pavesi,et al. Albumin for bacterial infections other than spontaneous bacterial peritonitis in cirrhosis. A randomized, controlled study. , 2012, Journal of hepatology.
[18] O. Yokosuka,et al. Emergency anticoagulation treatment for cirrhosis patients with portal vein thrombosis and acute variceal bleeding , 2012, Scandinavian journal of gastroenterology.
[19] P. Caraceni,et al. Albumin infusion in patients undergoing large‐volume paracentesis: A meta‐analysis of randomized trials , 2012, Hepatology.
[20] W. Koizumi,et al. Portal hemodynamic effects of sorafenib in patients with advanced hepatocellular carcinoma: a prospective cohort study , 2012, Journal of Gastroenterology.
[21] A. Bhalla,et al. Midodrine in patients with cirrhosis and refractory or recurrent ascites: a randomized pilot study. , 2012, Journal of hepatology.
[22] T. Reiberger,et al. The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma – a pilot study , 2012, Alimentary pharmacology & therapeutics.
[23] A. Gerbes,et al. Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity , 2011, Gut.
[24] O. Mir,et al. Reversible Decrease of Portal Venous Flow in Cirrhotic Patients: A Positive Side Effect of Sorafenib , 2011, PloS one.
[25] S. D. Lee,et al. Association of the G-protein and α2-adrenergic receptor gene and plasma norepinephrine level with clonidine improvement of the effects of diuretics in patients with cirrhosis with refractory ascites: a randomised clinical trial , 2010, Gut.
[26] D. Thabut,et al. Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis. , 2010, Gastroenterology.
[27] M. Mitterhauser,et al. Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. , 2009, Journal of hepatology.
[28] S. Raptis,et al. Intestinal decontamination improves liver haemodynamics in patients with alcohol‐related decompensated cirrhosis , 2009, Alimentary pharmacology & therapeutics.
[29] M. Mejías,et al. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats , 2009, Hepatology.
[30] Jaume Bosch,et al. Angiogenesis in liver disease. , 2009, Journal of hepatology.
[31] Jeffrey S. Morris,et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] Dieter Häussinger,et al. Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.
[33] M. Mejías,et al. Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet‐derived growth factor blockade in rats , 2007, Hepatology.
[34] J. Meunier,et al. Effects of clonidine on diuretic response in ascitic patients with cirrhosis and activation of sympathetic nervous system , 2006, Hepatology.
[35] F. Nevens,et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure , 2006, Critical care.
[36] Y. Mahida,et al. A pilot study to investigate the use of oxpentifylline (pentoxifylline) and thalidomide in portal hypertension secondary to alcoholic cirrhosis , 2004, Alimentary pharmacology & therapeutics.
[37] G. Jennings,et al. The Effect of Selective Intestinal Decontamination on the Hyperdynamic Circulatory State in Cirrhosis , 2003, Annals of Internal Medicine.
[38] R. Terg,et al. Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: A preliminary study , 2003, Hepatology.
[39] J. Calleja,et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement , 2003, Hepatology.
[40] T. Reynolds,et al. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. , 2000, Gastroenterology.
[41] M. Navasa,et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. , 1999, The New England journal of medicine.
[42] T. Poynard,et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: A meta‐analysis , 1999, Hepatology.
[43] C. Sabin,et al. Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage , 1998, Hepatology.
[44] R. Moreau,et al. Acute haemodynamic responses and inhibition of tumour necrosis factor-alpha by pentoxifylline in rats with cirrhosis. , 1996, Clinical science.
[45] L. Blendis,et al. Hepatic and portal vein thrombosis in cirrhosis: Possible role in development of parenchymal extinction and portal hypertension , 1995, Hepatology.
[46] P. Pizcueta,et al. Effects of low‐sodium diet and spironolactone on portal pressure in patients with compensated cirrhosis , 1994, Hepatology.
[47] R. Moreau,et al. Long-term sympathetic and hemodynamic responses to clonidine in patients with cirrhosis and ascites , 1992 .
[48] Yoon-Koo Kang,et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.
[49] J. Bosch,et al. Oral administration of clonidine in patients with alcoholic cirrhosis. Hemodynamic and liver function effects. , 1992, Gastroenterology.
[50] R. Moreau,et al. Hemodynamic effects of a clonidine‐induced decrease in sympathetic tone in patients with cirrhosis , 1987, Hepatology.
[51] J. Bruix,et al. Effects of alpha-adrenergic stimulation and beta-adrenergic blockade on azygos blood flow and splanchnic haemodynamics in patients with cirrhosis. , 1987, Journal of hepatology.